Introduction
Recombinant activated Factor VIIa (rFVIIa; NovoSeven Novo Nordisk, Princeton, NJ, USA) is approved by the US Food and Drug Administration to treat hemophilia patients with inhibitors to factor VIII or IX. rFVIIa functions locally, at the site of endothelial damage, by binding to tissue factor. This complex leads to the development of a fibrin clot by promoting thrombin formation and activating platelets. 1 rFVIIa is commonly used off-label to stop life-threatening bleeding refractory to conventional treatment with fresh frozen plasma (FFP) and cryoprecipitate in adults, children and infants. However, reports on the use of rFVIIa in infants and particularly premature infants are scarce.
Since 2005, rFVIIa has been used off-label as rescue treatment for critical bleeding refractory to conventional replacement therapy in infants admitted to the Duke Neonatal Intensive Care Unit. We report a series of patients who received rFVIIa, their treatment indications, dosage and clinical outcomes.
Methods
We conducted a retrospective cohort study of all infants receiving at least one dose of rFVIIa at Duke Neonatal Intensive Care Unit between January 2005 and July 2008. Clinical data and demographic information were collected by review of medical and pharmacy records. Age at treatment, number of rFVIIa doses and precipitating diagnosis warranting treatment were recorded. Coagulation studies, complete blood counts, blood product transfusions and blood culture results in the 72 h before and 72 h following administration of each rFVIIa dose were recorded. Hemostasis was clinically defined by the cessation of hemorrhage. The sampling technique for coagulation studies was carried out according to our Neonatal Intensive Care Unit practice guidelines that require peripheral blood draws as the primary mode of sampling.
Adverse outcomes, such as necrotizing enterocolitis, sepsis, thrombosis and mortality were noted. The diagnosis of necrotizing enterocolitis was made if the infant met stage IIA or greater of the modified Bell's criteria, which includes the radiographic finding of pneumatosis intestinalis. 2 Sepsis was defined by a positive blood culture.
All of the patients received blood products and vitamin K before the administration of rFVIIa. rFVIIa was administered at a dose of 90 mcg kg À1 , as a rapid IV push, at 2-h intervals and repeated until hemostasis was achieved.
During the study period, it was standard practice in the unit to use rFVIIa, in consultation with hematology-oncology service, for patients with refractory bleeding. No parental consent was obtained before rFVIIa administration. Data were analyzed using logistic regression, Fisher's exact and t-tests where appropriate. STATA 10 (College Station, TX, USA) was used for statistical analysis. This study was approved by the Duke University Institutional Review Board.
Results

Demographic data
We identified 18 infants who received at least one dose of rFVIIa during the study period. Sixteen infants (88%) were born prematurely. The median gestational age was 26 weeks (interquartile range, 24 to 32) and the median birth weight was 880 g (interquartile range, 694 to 2241). One to six doses of rFVIIa were administered at a median postnatal age of 9 days (interquartile range, 1 to 18). For the 18 infants included in the study, the clinical diagnoses that precipitated administration of rFVIIa included pulmonary hemorrhage (5), post surgical hemorrhage (6), gastrointestinal hemorrhage (1), intracranial hemorrhage (2), superficial skin hemorrhage (1) and disseminated intravascular coagulopathy (3) ( Table 1) .
Effectiveness
Hemostasis was achieved in 13 of 18 infants (72%) within 72 h of rFVIIa administration. A total of 9 of the 13 patients who achieved hemostasis did so after only one dose of FVIIa. The rate of hemostasis among preterm infants was similar, 69% (11/16). There were statistically significant differences in the following coagulation studies less than or equal to 72 h before and less than or equal to 72 h after rFVIIa administration: prothrombin time (24 vs 14 s; P ¼ 0.001) and activated partial thromboplastin time (144 vs 70 s; P ¼ 0.01) ( Table 2) .
The median volume of FFP infusions decreased significantly from 30 to 8 ml kg À1 in the 72 h before and after rFVIIa administration (P ¼ 0.02). Median transfusion volumes of packed red blood cells decreased from 30 to 10 ml kg À1 (P ¼ 0.35), platelets from 28 to 10 ml kg À1 (P ¼ 0.26) and cryoprecipitate decreased from 9 to 0 ml kg À1 (P ¼ 0.06). The total volume of blood products transfused before and after rFVIIa administration did not differ significantly (Table 3) . Analysis with exclusion of the six early deaths (deaths within 72 h of rFVIIa administration) did not (Table 3) .
Hematocrit increased from median of 25 to 27% (P ¼ 0.11) and fibrinogen levels increased from 120 to 184 mg 100 ml À1 (P ¼ 0.16) after rFVIIa therapy.
Safety
One infant in this cohort was found to have a non-occlusive aortic thrombus diagnosed by ultrasound 64 days after rFVIIa administration. The infant also had a history of umbilical arterial line placement during the first week of life. The patient did not require medical or surgical intervention for thrombosis, but died at 73 days of life secondary to respiratory failure and persistent chylothorax. Six (33%) infants died early, within 3 days of rFVIIa treatment. Causes of death included fulminant disseminated intravascular coagulopathy (n ¼ 4) and intracranial hemorrhage (n ¼ 2). Four additional infants died later, of the following nonbleeding complications: one of necrotizing enterocolitis 6 days after rFVIIa therapy, one of Escherichia coli sepsis 8 days after rFVIIa therapy and two of respiratory failure (73 days and 197 days after rFVIIa therapy) ( Table 4 ). Overall hospital mortality was 10/18 (56%).
Discussion
There are a number of reports describing the off-label use of rFVIIa in older infants and children for the treatment of refractory bleeding and prophylaxis for surgical procedures. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] However, the experience in premature infants is scarce. In this study, we report a large case series of premature infants treated with rFVIIa in the Neonatal Intensive Care Unit.
The indications for use of rFVIIa in this cohort are similar to the ones previously reported: pulmonary hemorrhage, gastrointestinal hemorrhage, necrotizing enterocolitis, subgaleal hemorrhage, subdural hematoma and post-surgical hemorrhage. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] The overall rate of hemostasis in our cohort (72%) is comparable to that of these published reports for infants of varying age groups. A similar rate (69%) was noted among preterm infants in our study. Hemostasis was achieved in all of the infants with pulmonary hemorrhage (5/5), ranging in gestational age from 24 to 32 weeks, after 1 to 3 doses of 90 mcg kg À1 of rFVIIa. Two case reports have described the successful use of rFVIIa for the treatment of preterm infants with pulmonary hemorrhage, Cetin et al. reported on a single case and Olomu on 2 infants, using doses of 50 to 120 mcg kg À1 . 16, 17 One infant in our cohort achieved hemostasis after receiving two doses of rFVIIa for gastrointestinal hemorrhage refractory to vitamin K and blood product transfusions, including FFP, cryoprecipitate, platelet and packed red blood cells. Similarly, Hunseler et al. treated one 27-week-old infant with a large gastrointestinal tract hemorrhage unresponsive to vitamin K, FFP and platelet transfusions. In that case, effective hemostasis was achieved after a single 110 mcg kg À1 dose of rFVIIa.
18 Overall, in our cohort, clinical hemostasis was not achieved in 5 of 18 infants (28%). The non responders included two premature infants with intracranial hemorrhage, two infants with disseminated intravascular coagulopathy and one infant with a large, hemorrhagic, sacrococcygeal teratoma (Table 4 , patients #7, 8, 10, 12 and 14) . It is important to note that 88% (16/18) of the infants in our study were premature with a median gestational age of 26 weeks and median age at treatment of 9 days. Young and investigators found that in their 17 infants less than 1 month, there was a 47% response rate compared with 61 to 72% response rates in the 122 older children who were studied. 27 Lack of response to rFVIIa may be related to on-going co-morbidities, bleeding from sites of invasive procedures, bleeding that is unresponsive to increased thrombin generation or more severe impairments in the hemostatic system (that is, thrombocytopenia, disseminated intravascular coagulopathy or immature vasculature), which reduce effectiveness of rFVIIa. Correcting thrombocytopenia and hypofibrinogenemia and treating underlying illnesses may improve the response rate. 27 Additional studies are specifically required in premature neonates to fully assess thrombin generation potential and thrombin generation in response to rFVIIa. Levels of most procoagulant and anticoagulant proteins are lower in preterm infants than term infants and older children. However, these levels may not predict the risk of bleeding or thrombosis. Global assays of coagulation, such as thrombin generation assays may be more predictive. 28 Tripodi et al. found that despite preterm infants having lower levels of procoagulant proteins than term infants, their thrombin generation potential was significantly higher. 29 No studies to date have measured thrombin generation in neonates in response to rFVIIa.
The need for blood product requirements before and after treatment with rFVIIa has not been examined closely. We noted statistical significant decreases in prothrombin time and activated partial thromboplastin time, as well as a reduction in plasma transfusion requirements, following rFVIIa administration. Although not statistically significant, our findings showed an overall trend toward an increase in fibrinogen level and a decrease in requirements of total volume of blood product transfusions.
In 2006, a review of all adverse events reported to the FDA (Food and Drug Administration) in the first 5 years of rFVIIa licensure was published. A total of 17 of the events occurred in patients with hemophilia, whereas 151 occurred during unlabeled use. The adverse events included cerebrovascular accidents (n ¼ 39), acute myocardial infarction (n ¼ 34), other arterial thrombosis (n ¼ 26), pulmonary embolism (n ¼ 32) and other venous thrombosis, including deep venous thromboses (n ¼ 42) and clotted devices (n ¼ 10). 30 Puetz et al. 31 retrospectively compared the rate of thromboses in 134 neonates who received 30 to 300 mcg kg À1 of rFVIIa for refractory bleeding vs 100 neonates who received FFP transfusions alone to treat coagulopathy. They reported no statistically significant difference in the incidence of thrombotic events between the two groups (7.5 vs 7%).
One thrombotic event was noted in our study. The nonocclusive aortic thrombus was found incidentally 64 days after treatment with rFVIIa. It is unlikely that this thrombus is related to rFVIIa treatment considering the lag between treatment and discovery of the clot and the history of umbilical arterial line in this patient during the first week of life.
rFVIIa doses of 40 to 300 mcg kg À1 have been used for varying indications and severity of bleeding in infants. Our strategy of using repeat doses of 90 mcg kg À1 of rFVIIa, during active bleeding only at a minimum of 2 h intervals, despite prolonged coagulation studies, rather than less frequent and larger doses, may be responsible for the low incidence of thrombotic adverse events in our study. Nonetheless, when rFVIIa is given close attention should be paid to signs of thrombosis.
Our overall mortality of 56% is reflective of the critically ill population. Almost 30% of the infants treated died due to bleeding complications. Further advancements in the use of hemostatic agents to prevent or stop bleeding may significantly reduce this mortality rate.
Although limited by small sample size and retrospective nature, this is the largest case series of rFVIIa use among premature infants, showing successful hemostasis and reduction of blood product requirements following rFVIIa administration.
Conclusions rFVIIa at doses of 90 mcg kg
À1 effectively contributed to achieving hemostasis in majority of the infants in our study, with severe acute hemorrhage. In extremely premature infants, for whom bleeding complications, such as pulmonary hemorrhage, are relatively common, the use of rFVIIa offers an alternative to large volume replacement with plasma or cryoprecipitate. Larger studies are needed to assess safety, pharmacokinetics, efficacy and longterm outcome in this population.
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